SCHEMBL17079289

SCHEMBL17079289

CCOC(=O)c1nnc(CCN)s1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 1/20 0.46
RECQL P46063 1/20 0.43
ALDH1A1 P00352 5/20 0.42
HPGD P15428 3/20 0.42
MAPT P10636 3/20 0.42
GAA P10253 2/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
NPSR1 Q6W5P4 1/20 0.40
CYP1A2 P05177 2/20 0.40
FHIT P49789 1/20 0.39
CYP2C9 P11712 1/20 0.39
AKT1 P31749 1/20 0.39
IRS1 P35568 1/20 0.39
GAB1 Q13480 1/20 0.39
LMNA P02545 2/20 0.38
CYP3A4 P08684 1/20 0.38
MAOA P21397 1/20 0.38
KDM4E B2RXH2 1/20 0.37
USP2 O75604 1/20 0.37
HSD17B10 Q99714 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL17871640 0.98 POLB (0.44) POLBRECQLALDH1A1HPGDMAPT
SCHEMBL19558977 0.87 RECQL (0.56) POLBRECQLALDH1A1HPGDMAPT
SCHEMBL31497061 0.87 NPSR1 (0.51) POLBRECQLALDH1A1HPGDMAPT
SCHEMBL15945408 0.83 GAA (0.50) POLBRECQLALDH1A1HPGDMAPT
SCHEMBL17402505 0.83 NPSR1 (0.58) POLBRECQLALDH1A1SMN1; SMN2NPSR1
SCHEMBL13477788 0.81 GAA (0.44) POLBRECQLALDH1A1HPGDMAPT
SCHEMBL17390707 0.81 NPSR1 (0.47) POLBRECQLALDH1A1HPGDMAPT
SCHEMBL17388809 0.80 RECQL (0.43) POLBRECQLALDH1A1HPGDMAPT
SCHEMBL17396790 0.80 RECQL (0.40) POLBRECQLALDH1A1HPGDMAPT
SCHEMBL17883755 0.80 RECQL (0.43) POLBRECQLALDH1A1HPGDMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9790219-B2 Compounds, compositions, and methods for increasing CFTR activity PROTEOSTASIS THERAPEUTICS, INC. (US) 2017-10-17 US disclosed
US-9790219-B2 Compounds, compositions, and methods for increasing CFTR activity PROTEOSTASIS THERAPEUTICS, INC. (US) 2017-10-17 US disclosed
US-9790219-B2 Compounds, compositions, and methods for increasing CFTR activity PROTEOSTASIS THERAPEUTICS, INC. (US) 2017-10-17 US disclosed
EP-3116501-A1 COMPOUNDS, COMPOSITIONS, AND METHODS FOR INCREASING CFTR ACTIVITY Proteostasis Therapeutics, Inc. (US) 2017-01-18 EP disclosed
US-20170001993-A1 COMPOUNDS, COMPOSITIONS, AND METHODS FOR INCREASING CFTR ACTIVITY PROTEOSTASIS THERAPEUTICS, INC. 2017-01-05 US disclosed
US-20170001993-A1 COMPOUNDS, COMPOSITIONS, AND METHODS FOR INCREASING CFTR ACTIVITY PROTEOSTASIS THERAPEUTICS, INC. 2017-01-05 US disclosed
US-20170001993-A1 COMPOUNDS, COMPOSITIONS, AND METHODS FOR INCREASING CFTR ACTIVITY PROTEOSTASIS THERAPEUTICS, INC. 2017-01-05 US disclosed
WO-2015138909-A1 COMPOUNDS, COMPOSITIONS, AND METHODS FOR INCREASING CFTR ACTIVITY PROTEOSTASIS THERAPEUTICS, INC. (US) 2015-09-17 WO disclosed
WO-2015138909-A1 COMPOUNDS, COMPOSITIONS, AND METHODS FOR INCREASING CFTR ACTIVITY PROTEOSTASIS THERAPEUTICS, INC. (US) 2015-09-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170001993-A1 COMPOUNDS, COMPOSITIONS, AND METHODS FOR INCREASING CFTR ACTIVITY CFTR, ABCB4, KEAP1 POLB 1649/4885RECQL 71/4885ALDH1A1 3095/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.